文献速递真菌感染

侵袭性霉菌感染诊断的实验室创新:哪些相关,哪些不相关

Laboratory innovations to diagnose invasive mould infections-what is relevant, what is not?
PubMed 文献 · Clin Microbiol Infect · 2025-10-30

本文为叙述性综述,检索无日期限制的文献,评估侵袭性霉菌感染诊断新进展。快速侧流 assay 和单样本化学发光免疫 assay 可检测曲霉抗原,Mucorales PCR 改善毛霉病诊断,mNGS 扩大检测但受成本限制,宿主反应 assay 尚在研究阶段。

要点

  • 曲霉抗原检测的快速侧流法和单样本化学发光法可在许多医院实施。
  • Mucorales PCR 可改善毛霉病诊断,包括合并感染时。
  • 多模式病原体策略整合抗原、靶向 PCR 和选择性 mNGS 可实现更早更准确诊断。

核心结论

  • 多模式病原体策略整合抗原 assay、靶向 PCR 和选择性 mNGS 可实现更早、更准确、更全面的 IMI 诊断,最终改善临床结局。
  • 对快速、准确、非侵入性 IMI 诊断测试的需求仍然存在,宿主反应 assay 尚未临床可用。

研究设计与样本

  • 叙述性综述,文献检索无日期限制,包括实验和临床研究、系统综述和荟萃分析。

主要发现

  • 快速侧流 assay 和单样本化学发光免疫 assay 检测血液和支气管肺泡灌洗液中曲霉抗原,现可补充酶免疫 assay。
  • 尿聚糖和铁载体等新靶点在多种生物基质中显示诊断 IMI 的潜力。
  • 曲霉和 Mucorales 的靶向 PCR 比传统方法更早检测,且可快速检测烟曲霉耐药,但孤立曲霉 PCR 阳性难以解读。
  • mNGS 扩大病原体检测,但受成本和技术及解读挑战限制。
  • 基于宿主免疫反应的 assay(功能性免疫 assay 和生化标志物)显示前景但仍处于研究阶段。

关键数值与推荐

  • 由于不同商业可用的测试形式,曲霉抗原检测 assay 现可在许多医院实施。
  • 实施 Mucorales PCR 测试改善毛霉病诊断,包括合并感染时。
  • 多模式病原体策略整合抗原 assay、靶向 PCR 和选择性 mNGS 可实现更早、更准确、更全面的 IMI 诊断。

临床怎么用

  • 曲霉抗原检测 assay 可在许多医院实施,用于血液和支气管肺泡灌洗液检测。
  • 实施 Mucorales PCR 测试以改善毛霉病诊断,包括合并感染时。
  • 采用多模式病原体策略,整合抗原 assay、靶向 PCR 和选择性 mNGS 以更早更准确诊断 IMI。

局限性

  • 孤立曲霉 PCR 阳性难以解读。
  • mNGS 受成本和技术及解读挑战限制。
  • 宿主反应 assay 尚未临床可用。
  • 需要前瞻性多中心研究标准化诊断阈值、验证新诊断标志物并评估对患者结局和成本效果的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive mould infections (IMI) carry high morbidity and mortality. Conventional diagnostics-histopathology, culture and microscopy-rely on invasive sampling and lack sensitivity, particularly during early phases of infection. Rare and mixed mould infections are frequently diagnosed too late or missed. OBJECTIVES: To provide a narrative review of recent innovations in diagnosing IMIs, highlighting advances, identifying areas where progress remains limited, and assessing gaps in current diagnostic algorithms to guide future directions. SOURCES: We performed a literature search regarding diagnostic methods for IMIs without date restrictions, including experimental and clinical studies, systematic reviews and meta-analyses. CONTENT: Rapid lateral flow assays and single-sample chemiluminescent immunoassays for detecting Aspergillus antigens in blood and bronchoalveolar lavage fluid now complement enzyme immunoassays. Novel targets, such as urinary glycans and siderophores in various biological matrices, show potential to diagnose IMI. Targeted PCRs for Aspergillus and Mucorales enable earlier detection than conventional methods and rapid detection of resistance in case of A. fumigatus, although isolated Aspergillus PCR positivity is challenging to interpret. Metagenomic next-generation sequencing expands pathogen detection but is limited by costs and technical and interpretative challenges. A shift towards assays based on the host immune response (functional immune assays and biochemical markers) shows promise but remains investigational. IMPLICATIONS: Due to different commercially available test formats, Aspergillus antigen detection assays can now be implemented in many hospitals. Implementation of Mucorales PCR tests improves the diagnosis of mucormycosis also in the setting of coinfections. Multimodal pathogen-based strategies that integrate antigen assays, targeted PCRs, and, in select cases, metagenomic next-generation sequencing enable earlier, more accurate, and comprehensive diagnosis of IMIs, ultimately improving clinical outcomes; but the need for rapid, accurate, noninvasive diagnostic tests for IMIs remains. Host-response-based assays are not yet clinic-ready. Prospective multicentre studies are needed to standardize diagnostic thresholds, validate novel diagnostic markers and to evaluate impact on patient outcomes and cost-effectiveness.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Vanbiervliet Y, Aerts R, Maessen L, et al. Laboratory innovations to diagnose invasive mould infections-what is relevant, what is not? Clin Microbiol Infect. 2025. PMID: 41173342. doi:10.1016/j.cmi.2025.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。